Form 4: Arrowhead Director Sells Shares Under 10b5-1 Plan

Arrowhead Pharmaceuticals director Mauro Ferrari reported the sale of 7,530 common shares at $70 each, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Mauro Ferrari, a Director at Arrowhead Pharmaceuticals, Inc. (ARWR), reported a transaction involving the company's common stock.
• On December 26, 2025, Ferrari disposed of 7,530 shares of common stock.
• The shares were sold at a price of $70 per share.
• This transaction was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by the reporting person.
• Following this transaction, Mauro Ferrari beneficially owns 69,053 shares of common stock directly.
• The remaining beneficial ownership includes previously reported shares underlying Restricted Stock Units, some of which are still subject to vesting conditions.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale can sometimes be viewed negatively, the fact that it was executed under a pre-arranged 10b5-1 plan mitigates concerns that it's a reaction to adverse company-specific news. It's a routine, planned transaction.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction rather than a reaction to recent company performance or news.

Negatives

• A director's sale of shares, even if planned, can sometimes be perceived negatively by investors as it reduces insider ownership.

Risks

• Potential negative market perception due to an insider selling shares, which could lead to short-term stock price volatility.
• The reduction in direct insider ownership, although minor in this instance, could be viewed as a slight decrease in alignment between management and shareholder interests.

Future Outlook

NA

Industry Context

This filing is a standard insider transaction report and does not provide information directly related to broader industry trends or competitive landscape for Arrowhead Pharmaceuticals. Insider sales are common across all industries.

Stakeholder Impact

• Shareholders: May interpret the director's sale differently; some might see it as a normal part of financial planning, while others might view it as a slight reduction in insider confidence. The impact is likely minimal given the 10b5-1 plan.
• Employees, Customers, Suppliers, Creditors: No direct impact from this specific insider transaction.

Key Dates

Recommendation

A single insider sale, particularly one executed under a pre-arranged 10b5-1 trading plan, typically does not warrant a change in investment recommendation. It's a routine financial event for the individual, not necessarily indicative of a fundamental shift in the company's prospects. Investors should continue to evaluate Arrowhead Pharmaceuticals based on its core business performance, pipeline, and broader market conditions.

Keywords

ARWR, Arrowhead Pharmaceuticals, Mauro Ferrari, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Director Transaction